DelMar Pharmaceuticals is a brand dedicated to the development of innovative cancer therapies for patients who are failing or resistant to current treatment regimens. They have partnered with distinguished academic and clinical research institutions worldwide to support the advancement of their novel cancer therapies. DelMar's mission is to improve the lives of patients and their families, and their values drive every decision and action they take.

With a strong focus on patient outcomes and quality of life, they conduct research and develop cancer therapies that meet the highest standards of excellence. DelMar's lead product candidate, VAL-083, is a groundbreaking small molecule DNA-targeting agent with a unique mechanism of action that results in DNA double strand breaks and cancer cell death. Clinical trials for VAL-083 offer hope for patients where other treatments may not be effective.

By partnering with renowned research centers globally, DelMar Pharmaceuticals continues to advance their platform strategy, addressing unmet needs in the treatment of drug and immune-resistant cancer. Their team of experienced leaders brings expertise in drug discovery and development, as well as translational cancer biology. If you're looking to join a team that is making a real difference in the fight against cancer, join DelMar Pharmaceuticals and be part of their mission to change the game in cancer therapeutics